Bupropion is an atypical antidepressant licensed in the UK for smoking cessation, but it is not approved as a standalone treatment for obesity. However, a combination product containing bupropion and naltrexone (Mysimba) has received MHRA authorisation for weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with weight-related comorbidities. Bupropion functions as a noradrenaline-dopamine reuptake inhibitor, and when combined with naltrexone, it may enhance appetite suppression and support adherence to lifestyle modifications. This article examines the evidence, eligibility criteria, safety considerations, and alternatives for bupropion treatment for obesity in the UK.

What Is Bupropion and How Does It Work for Weight Loss?

Bupropion is an atypical antidepressant primarily licensed in the UK for smoking cessation (as Zyban). It is not licensed in the UK for the treatment of major depressive disorder, although it may be prescribed off-label for this indication. Bupropion functions as a noradrenaline-dopamine reuptake inhibitor (NDRI), modulating neurotransmitter activity in the central nervous system. Unlike selective serotonin reuptake inhibitors (SSRIs), bupropion has minimal effect on serotonin reuptake, which may explain its distinct side effect profile and potential metabolic effects.

The mechanism by which bupropion may influence weight is not fully understood, but it is thought to involve hypothalamic pathways that regulate appetite and energy expenditure. By increasing dopaminergic and noradrenergic activity, bupropion may reduce food cravings and enhance satiety signals. Clinical observations have noted that patients taking bupropion for smoking cessation sometimes experience modest weight loss, which has prompted investigation into its potential role in obesity management.

It is important to note that bupropion is not licensed as a standalone treatment for obesity in the UK, and its use for this purpose would be off-label. However, a combination product containing bupropion and naltrexone (Mysimba) has received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of weight-related comorbidities. Mysimba is a prolonged-release formulation that requires a defined weekly titration schedule as per the Summary of Product Characteristics (SmPC). The naltrexone component, an opioid receptor antagonist, is believed to work synergistically with bupropion to enhance appetite suppression and improve adherence to lifestyle modifications.

Mysimba should be taken with food, but high-fat meals should be avoided as they can increase bupropion exposure and raise the risk of adverse effects, including seizures.

Clinical Evidence for Bupropion in Obesity Treatment

The evidence base for bupropion in obesity treatment primarily derives from studies of the bupropion-naltrexone combination rather than bupropion monotherapy. The pivotal Contrave Obesity Research (COR) programme, which included several large randomised controlled trials (COR-I, COR-II, COR-BMOD, and COR-Diabetes), demonstrated that patients receiving bupropion-naltrexone achieved significantly greater weight loss compared to placebo when combined with lifestyle intervention. Participants typically lost an additional 4–5% of their baseline body weight (placebo-subtracted) over 56 weeks, with some studies showing up to 9% total weight loss in responders.

A systematic review and meta-analysis published in Obesity Reviews confirmed that bupropion-naltrexone was associated with clinically meaningful weight reduction, defined as at least 5% loss of initial body weight. Importantly, the combination also demonstrated improvements in cardiometabolic parameters, including reductions in waist circumference, triglycerides, and HbA1c in patients with type 2 diabetes. However, the magnitude of weight loss was generally modest compared to newer agents such as GLP-1 receptor agonists.

Evidence for bupropion monotherapy in obesity is limited and inconsistent. Some small trials have suggested modest weight loss of 2–3 kg over several months, but these findings have not been robust enough to support regulatory approval for this indication. Bupropion monotherapy is not included as an option in NICE guidance for obesity management because it is unlicensed for this indication in the UK. Clinicians should be aware that the evidence supporting bupropion-naltrexone is stronger than for bupropion alone, and prescribing decisions should reflect current licensing and guidance.

Who Can Use Bupropion for Weight Management in the UK?

In the UK, bupropion-naltrexone (Mysimba) is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidaemia. Treatment should only be initiated as part of a comprehensive weight management programme that includes dietary modification, increased physical activity, and behavioural support. NICE guidance (CG189) on obesity management emphasises that pharmacological interventions should be considered only after dietary, exercise, and behavioural approaches have been attempted.

Before prescribing bupropion-naltrexone, clinicians must conduct a thorough assessment to exclude contraindications. Absolute contraindications include:

• Uncontrolled hypertension (clinical judgement required; no fixed numeric threshold is defined in the SmPC)

• Seizure disorders or conditions that lower seizure threshold

• Current or previous diagnosis of bulimia or anorexia nervosa

• Bipolar disorder

• Concurrent use of monoamine oxidase inhibitors (MAOIs)

• Acute alcohol or benzodiazepine withdrawal

• Known hypersensitivity to bupropion or naltrexone

• Chronic opioid or opioid agonist use (including methadone, partial agonists, or mixed agonist/antagonists)

• Acute opioid withdrawal

• Severe hepatic impairment

• End-stage renal disease

• Tumour of the central nervous system

• Pregnancy

• Concurrent use of other bupropion-containing products

Mysimba is not recommended in patients under 18 years of age. Caution is advised in older adults, and use should be avoided in those over 75 years.

Patients must be opioid-free for at least 7–10 days before starting naltrexone-containing products to avoid precipitated withdrawal. Clinicians should be aware of important drug interactions: bupropion is metabolised by CYP2B6 (inducers and inhibitors may alter exposure) and inhibits CYP2D6 (potentially increasing levels of co-administered CYP2D6 substrates). Caution is required with medications that lower seizure threshold.

Mysimba is initiated using a weekly dose titration schedule as per the SmPC. Treatment response must be evaluated after 16 weeks; if patients have not achieved at least 5% weight loss by this point, treatment must be discontinued. Regular monitoring of blood pressure, heart rate, and mental health status is essential throughout treatment. Mysimba is contraindicated during pregnancy, and effective contraception should be discussed with women of childbearing potential. Patients should be counselled about the importance of adherence to lifestyle modifications, as pharmacotherapy alone is unlikely to produce sustained weight loss.

Side Effects and Safety Considerations

Bupropion-naltrexone is associated with a range of adverse effects that require careful patient counselling and monitoring. The most commonly reported side effects include nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhoea. Nausea is particularly prevalent during treatment initiation and can be minimised by gradual dose titration and taking the medication with food (avoiding high-fat meals). Many gastrointestinal symptoms improve over the first few weeks of treatment.

Cardiovascular effects warrant particular attention. Bupropion-naltrexone can cause modest increases in blood pressure and heart rate. Baseline and periodic monitoring of blood pressure and pulse is required as per the SmPC. Patients with pre-existing cardiovascular disease or uncontrolled hypertension should be carefully evaluated before treatment initiation. If sustained increases in blood pressure occur, dose reduction or discontinuation may be necessary.

Neuropsychiatric effects are an important safety consideration. Bupropion has been associated with an increased risk of seizures, particularly at higher doses or in patients with predisposing factors such as eating disorders, head trauma, or concurrent use of medications that lower seizure threshold. The risk is dose-dependent, and high-fat meals should be avoided as they increase bupropion exposure and seizure risk. Patients should be advised to discontinue treatment immediately if they experience a seizure.

There have been post-marketing reports of neuropsychiatric symptoms including depression, suicidal ideation, anxiety, and agitation in patients taking bupropion for smoking cessation. While causality has not been definitively established, the MHRA advises that patients and carers should be alert to changes in mood or behaviour, particularly during treatment initiation. Any concerning symptoms should prompt urgent medical review. Patients with a history of depression or other psychiatric disorders require particularly careful monitoring.

Hepatic considerations: Elevations in liver transaminases have been reported. Mysimba should be avoided in patients with severe hepatic impairment, and liver function should be monitored if symptoms suggestive of hepatic dysfunction develop. Ocular effects: Mydriasis (pupil dilation) has been reported, which may trigger angle-closure glaucoma in susceptible individuals. Patients should be advised to seek immediate medical attention if they experience eye pain, changes in vision, or swelling or redness around the eye.

Patients should be advised to moderate or avoid alcohol and to exercise caution when driving or operating machinery if they experience dizziness or drowsiness. Patients and healthcare professionals are encouraged to report any suspected adverse reactions via the MHRA Yellow Card Scheme (available at yellowcard.mhra.gov.uk or via the Yellow Card app).

Alternatives to Bupropion for Weight Loss

Several pharmacological alternatives to bupropion-naltrexone are available for weight management in the UK, each with distinct mechanisms of action, efficacy profiles, and safety considerations. Orlistat (Xenical, Alli) is a lipase inhibitor that reduces dietary fat absorption by approximately 30%. It is available both on prescription and over-the-counter at lower doses. NICE recommends orlistat for adults with a BMI of 28 kg/m² or above with associated risk factors, or 30 kg/m² or above. Typical weight loss is modest (2–3 kg more than placebo), and gastrointestinal side effects such as oily stools and faecal urgency are common, particularly with high-fat meals.

GLP-1 receptor agonists represent a newer and increasingly important class of anti-obesity medications. Liraglutide 3.0 mg (Saxenda) and semaglutide 2.4 mg (Wegovy) are licensed for weight management in the UK. These agents work by mimicking the incretin hormone GLP-1, which enhances satiety, slows gastric emptying, and reduces appetite. Clinical trials have demonstrated superior weight loss compared to older agents, with average reductions of 5–15% of baseline body weight. Common side effects include nausea, vomiting, and diarrhoea. NICE has issued technology appraisals defining eligibility criteria for these agents in specific populations; availability is subject to local commissioning decisions.

Non-pharmacological interventions remain the cornerstone of obesity management. Structured lifestyle programmes incorporating dietary modification, physical activity, and behavioural therapy should always be the first-line approach. NICE recommends multicomponent interventions delivered by trained professionals, with ongoing support to maintain weight loss. For individuals with severe obesity (BMI ≥40 kg/m² or ≥35 kg/m² with comorbidities) who have not achieved adequate weight loss with conservative measures, bariatric surgery may be considered. Procedures such as gastric bypass and sleeve gastrectomy typically result in substantial and sustained weight loss (25–30% of baseline weight) and improvement in obesity-related comorbidities. Referral criteria and patient selection should follow NICE guidance (CG189), with assessment in a specialist multidisciplinary service and careful consideration of surgical risks and the need for lifelong follow-up and nutritional supplementation.

Frequently Asked Questions